Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with or without tocilizumab for advanced biliary tract cancer
2018-004826-27Phase 2Terminated
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in biliary cancer and cholangiocarcinoma (CCA) comparing Gemcitabine + cisplatin + tocilizumab with Gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival rate at 12 months. Started Feb 2019; status: terminated.
02
Drugs
tocilizumabgemcitabinecisplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2018-004826-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004826-27.